{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:46Z","timestamp":1791357286055,"version":"4.3.1"},"reference-count":6,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T00:00:00Z","timestamp":1343174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Aust N Z J Psychiatry"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1177\/0004867412455702","type":"journal-article","created":{"date-parts":[[2012,10,26]],"date-time":"2012-10-26T08:11:34Z","timestamp":1351239094000},"page":"1106-1107","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["HLA-B*1502 screening in carbamazepine and lamotrigine candidates of Asian background"],"prefix":"10.1177","volume":"46","author":[{"given":"Islam","family":"Hassan","sequence":"first","affiliation":[{"name":"Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2012,7,25]]},"reference":[{"key":"bibr1-0004867412455702","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009717"},{"key":"bibr2-0004867412455702","doi-asserted-by":"publisher","DOI":"10.1038\/428486a"},{"key":"bibr3-0004867412455702","doi-asserted-by":"publisher","DOI":"10.2217\/17410541.2.3.225"},{"key":"bibr4-0004867412455702","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.09.162"},{"key":"bibr5-0004867412455702","doi-asserted-by":"publisher","DOI":"10.1027\/0838-1925.14.4.143"},{"key":"bibr6-0004867412455702","unstructured":"U.S. Food and Drug Administration (2007) Information for Healthcare Professionals: Dangerous or even fatal skin reactions \u2013 Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics. FDA Alert 12\/12\/2007. Available at: www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124718.html (accessed 7 July 2012)."}],"container-title":["Australian & New Zealand Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0004867412455702","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0004867412455702","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0004867412455702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:54:43Z","timestamp":1777373683000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0004867412455702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,25]]},"references-count":6,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1177\/0004867412455702"],"URL":"https:\/\/doi.org\/10.1177\/0004867412455702","relation":{},"ISSN":["0004-8674","1440-1614"],"issn-type":[{"value":"0004-8674","type":"print"},{"value":"1440-1614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,25]]}}}